Table 2.
FDA-approved drugs with epigenetic effects
| Drugs | Classification | Indicated disease | Approved year |
|---|---|---|---|
| Procainamide | DNMTi | Cardiac arrhythmia | 1950 |
| Hydralazine | DNMTi | Hypertension | 1953 |
| Valproic acid | HDACi | Epilepsy/seizures | 1978 |
| Nesiritide | LncRNA upregulator | Heart failure | 2001 |
| Azacitidine | DNMTi | MDS | 2004 |
| Vorinostat | HDACi | CTCL | 2006 |
| Decitabine | DNMTi | MDS | 2006 |
| Romidepsin | HDACi | CTCL/PTCL | 2009/2011 |
| Ruxolitinib | JAK1/2 inhibitor | Myelofibrosis | 2011 |
| Belinostat | HDACi | PTCL | 2015 |
| Panobinostat | HDACi | MM | 2015 |
MDS myelodysplastic syndrome, CTCL cutaneous T cell lymphoma, PTCL peripheral T cell lymphoma, MM multiple myeloma